SMTL ID : 7nxj.1 (1 other biounit)

Crystal structure of human Cdk13/Cyclin K in complex with the inhibitor THZ531

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.36 Å

Oligo State

hetero-1-1-mer

Ligands

1 x 5I1: N-[4-[(3R)-3-[[5-chloranyl-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]carbonylphenyl]-4-(dimethylamino)butanamide(Non-covalent)

5I1.1: 17 residues within 4Å: Chain A: I.19, E.21, A.40, I.73, F.99, E.100, Y.101, M.102, D.103, D.105, M.107, E.111, L.152, Q.323, D.324, C.325, E.327 9 PLIP interactions: 9 interactions with chain A Hydrophobic interactions: A:Q.323 Hydrogen bonds: A:K.42, A:K.42, A:M.102, A:M.102, A:C.325 Water bridges: A:D.163 Salt bridges: A:E.111, A:E.327

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Jiang, B. et al., Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. Eur.J.Med.Chem. (2021)

Release Date

2021-05-12

Peptides

Cyclin-dependent kinase 13: A
Cyclin-K: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

Cyclin-dependent kinase 13

Cyclin-K

Related Entries With Identical Sequence